Vertex Reports meta-analysis Data for Brigatinib in Diffuse large B-cell lymphoma

Vertex today announced meta-analysis results for brigatinib in patients with diffuse large B-cell lymphoma. The study demonstrated that brigatinib reduces adverse events compared to standard of care or placebo. These results provide important insights into the treatment of diffuse large B-cell lymphoma and support the continued development of brigatinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.